Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. GRADE profile for outcomes for studies investigating patients with psoriasis

| | | | Certainty asse | Summary of the results | | | |
|---|----------------------|----------------------|----------------------|--------------------------|----------------------|-------------------------------------|---|
| Number of particip ants (studies) | Risk of bias | Inconsi stency | Indirectne ss | Imprecisio n | Publicatio n bias | Overall certainty of evidence | |
| Disease sev | verity (follo | ow up: 6-12 | months; meas | sured with: PA | SI, BSA, PtG | A, IGA) | |
| 394 (3 RCTs) | serious ^a | serious ^b | not serious | not serious | not identified | ⊕⊕⊖⊖ Low | The outcomes were displayed utilizing various scoring systems. While no substantial distinction was observed between the intervention and control groups, a slight advantage leaned towards the intervention group, albeit grounded in evidence of limited certainty. |
| Quality of | life (follow | up: 6-12 m | onths; measu | red with: DLQ | I, CDLQI an | d Skindex) | |
| 394 (3 RCTs) | serious ^a | serious ^b | not serious | not serious | not identified | ⊕⊕⊖⊖ Low | The outcomes were displayed utilizing various scoring systems. No substantial distinction was observed between the intervention and control groups. |
| Safety | | | | | | | |
| 330 (2 RCTs) | serious ^a | serious ^b | not serious | serious ^c | not identified | ⊕○○○ Very low | Two studies reported no clinical difference in adverse events of number of irritation events during treatment |
| Cost-effica | ıcy | | | | | | |
| 64 (1 RCT) | serious ^a | not serious | serious ^d | not serious ^e | not identified | ⊕○○○ Very low | An observed benefit revealed an incremental cost- effectiveness ratio of \$16,318.75 per QALY saved for the in-office group in comparison to the online group. These findings stem from a limited participant pool within a specific context, thus rendering the results less robust. |
| Mobility (1 | follow up: (| o months) | | | | | |
| 296 (1 RCT) | serious ^a | not serious | serious ^d | not serious | not identified | ⊕⊕○○ Low | A solitary study indicated a significant reduction in travel distance, transportation, and waiting time for in-person visits. While the advantages for the intervention group seem intuitive, the extent of these benefits remains uncertain. |

| Certainty assessment | | | | | | | Summary of the results |
|----------------------|----------------------|----------------|-------------|------------------------------|-------------------|------------------|--|
| 64 (1 RCT) | serious ^a | not serious | not serious | very serious ^e | not identified | ⊕○○○ Very low | A single study suggested that the frequency of online visits was 1.7 times lower compared to in-person visits. However, these results are surrounded by a high degree of uncertainty. |

Explanations

- a. There are some concerns regarding the potential for bias, randomization procedures, and blinding in certain cases.
- b. Results are clinically heterogeneous. The results however show a consistent homogenous trend.
- c. Very little results were presented.
- d. The findings originate from a remote area and might hold lesser relevance for more urbanized regions.
- e. Results were based on a study with 64 participants.

BSA: Body Surface Area; (C)DLQI: (Children's) Dermatology Life Quality Index; IGA: Investigator Global Assessment; PASI: Psoriasis Area and Severity Index; PtGA: Patient Global Assessment; QALY: Quality-Adjusted Life Years; RCT: Randomized Controlled Trial

Table SII. GRADE profile for outcomes for studies investigating patients with atopic dermatitis

| | | Summary of the results | | | | | |
|----------------------------------|----------------------|------------------------|--------------------------|---------------------------|---------------------|-------------------------------|---|
| Number of participants (studies) | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence | |
| Disease sever | ity (follow | up: 12 months; 1 | neasured with: | POEM, IGA, SCO | ORAD) | 1 | |
| 446 (3 RCTs) | serious ^a | serious ^b | not serious | not serious | not identified | ⊕⊕○○ Low | The outcomes were displayed utilizing various scoring systems. No substantial distinction was observed between the intervention and control groups. |
| Quality of life | e (follow uj | p: 12 months; me | easured with: D | LQI, CDLQI and | Skindex) | | |
| 348 (2 RCTs) | serious ^a | serious ^b | not serious | not serious | not identified | ⊕⊕○○ Low | The outcomes were displayed utilizing various scoring systems. No substantial distinction was observed between the intervention and control groups. |
| Cost-efficacy | (follow up | : mean 12 month | s) | | L | | |
| 192 (1 RCT) | serious ^a | not serious | not serious ^c | very serious ^d | not identified | ⊕○○○ Very low | An observed benefit revealed an incremental cost-effectiveness ratio of \$16,318.75 per QALY saved for the inoffice group in comparison to the online group. These findings stem from a limited participant pool within a specific context, thus rendering the results less robust. |

b. Results are clinically heterogeneous. The results however show a consistent homogenous trend.

(C)DLQI: (Children's) Dermatology Life Quality Index; IGA: Investigator Global Assessment; POEM: Patient-Oriented Eczema Measure; QALY: Quality-Adjusted Life Years; RCT: Randomized Controlled Trial; SCORAD: Severity Scoring of Atopic Dermatitis

c. The findings originate from a remote area and might hold lesser relevance for more urbanized regions.

d. Results were based on a study with one study with 192 participants.